What are Mission Vision & Core Values of Sandoz Group Company?

What drives Sandoz Group's purpose and direction?

Sandoz Group, spun off from Novartis in late 2023, anchors its strategy in affordable access to off-patent medicines and biosimilars. With about 20,000 employees, it balances cost leadership with innovation to serve global healthcare needs.

Sandoz’s mission and vision guide R&D, capital allocation, and market expansion amid pricing pressure and supply-chain complexity. By July 2025, its core values emphasize access, quality, and sustainability to sustain leadership in generics and biosimilars.

What are Mission Vision & Core Values of Sandoz Group Company? Explore strategic implications and competitive positioning in the sector: Sandoz Group Porter's Five Forces Analysis

Sandoz focuses on widening patient access to generics and biosimilars, prioritizing affordability, supply stability and partnerships with health systems to reach global patient populations.

Access-first approach

Prioritizes patient reach over exclusivity, delivering affordable generics and biosimilars to health systems worldwide.

Product focus

Concentrates on high-quality generics, biosimilars and essential medicines to lower treatment costs.

Supply resilience

Invested $400,000,000 in Austrian manufacturing upgrades to secure antibiotic supply for millions.

Democratizing biologics

Launched biosimilar adalimumab across multiple markets in 2024–2025, offering cost-effective alternatives to top-selling biologics.

Customer-centric value

Works with payers and providers to improve affordability and long-term sustainability of healthcare budgets.

Strategic differentiation

Positions itself as a partner to healthcare systems, not just a manufacturer, aligning with Sandoz Group purpose and company values.

Pioneering access for patients: mission centers on affordable generics and biosimilars, supply investments and partnerships to expand global treatment access while supporting healthcare sustainability. Read more on Revenue Streams & Business Model of Sandoz Group: Revenue Streams & Business Model of Sandoz Group

Sandoz’s vision targets market leadership and stakeholder value, shifting generics toward high-value biosimilars with a pipeline of over 25 molecules and aiming for mid-single-digit net sales CAGR (2024–2028) and 24%–26% core EBITDA by 2028.

Market Leadership

Positioned as the global leader in generics and top-tier biosimilars, holding #1 in generic antibiotics.

Value Creation

Focus on delivering consistent shareholder returns after public listing with improved margins and growth.

Biosimilars Pipeline

Developing over 25 biosimilar molecules to move generics into complex therapies.

Financial Targets

Targets mid-single-digit net sales CAGR (2024–2028) and core EBITDA margin 24%–26% by 2028.

Corporate Purpose

Aligns Sandoz Group purpose with accessible medicines and sustainable growth across markets.

Stakeholder Trust

Strives to be the most valued company by customers, patients, and investors through reliable supply and innovation.

Vision encapsulates leadership in generics and value creation, backed by a 25+-molecule biosimilar pipeline and specific financial targets through 2028.

Mission, Vision & Core Values of Sandoz Group

Sandoz company values center on patient access, scientific rigor and responsible growth; these core values guide daily decisions and long-term strategy as the group pursues global generics and biosimilars reach. The framework supports a nimble, independent culture aligned with the Sandoz Group purpose and Sandoz Mission Vision Core Values.

Entrepreneurial Ownership

Employees are encouraged to act like owners, enabling decentralized decisions and rapid market responses; this drove fast expansion into oncology biosimilars in emerging markets.

Agility and Speed

Streamlined R&D and regulatory pathways accelerate time-to-market; exemplified by early biosimilar natalizumab filings and adaptive manufacturing to address drug shortages.

Accountability to Patients and Markets

Robust Quality Management Systems and transparent ESG reporting underpin commitments such as reaching 500 million patients annually by 2025 and disciplined financial guidance.

Integrity and Compliance

Strong compliance frameworks and ethical practices build regulator and patient trust, differentiating the company in quality-sensitive markets.

Explore how Sandoz Mission Vision Core Values shape Sandoz strategic goals and corporate identity in the next chapter: how mission and vision influence the company's strategic decisions. Read also Owners & Shareholders of Sandoz Group

The mission and vision guide strategic decisions by prioritizing patient access, portfolio focus and capital allocation; they shape product selection, M&A and operational efficiency. Clear purpose and values ensure consistent choices across R&D, manufacturing and commercial execution.

Sandoz Mission, Vision & Core Values Overview

The company frames its purpose around increasing global access to medicines while aiming to be the most valued generics and biosimilars partner.

• Mission: improve patient access to high-quality medicines worldwide
• Vision: be the most valued generics and biosimilars company
• Core values: patient focus, integrity, performance, collaboration, and agility
• Strategic focus: complex generics, biosimilars, hospital therapeutics

Purpose Drives Portfolio Choices

Purpose-led strategy favors biosimilars and complex generics with highest patient impact and margin potential.

Capital Allocation

Investment prioritized for high-margin biosimilars development over low-margin legacy generics.

M&A as Strategic Tool

Acquisitions target portfolio gaps that improve access—example: 2024 Mycamine acquisition to expand hospital anti-infectives.

Operational Excellence

Sandoz Excellence System focuses on manufacturing efficiency and waste reduction to support affordability goals.

Performance Metrics

15 percent biosimilar net sales growth reported in 2024, continuing into 2025; used to validate strategy.

Leadership Alignment

CEO statements emphasize independence and focus on access-driven purpose since separation from prior parent company.

Explore how mission and vision translate into concrete initiatives and metrics; read the next chapter: Core Improvements to Company's Mission and Vision.

Influence: The mission and vision are the primary drivers of Sandoz’s Act and Grow strategy, steering focus toward complex generics and biosimilars—illustrated by the 2024 acquisition of Mycamine—and shaping capital allocation to prioritize biosimilar development; leadership and the Sandoz Excellence System operationalize these priorities, reflected in 15 percent biosimilar net sales growth in 2024 and continued momentum into 2025. Brief History of Sandoz Group

Four core improvements can sharpen Sandoz Group's mission and vision to reflect 2025 industry shifts toward digital transformation and environmental sustainability. These targeted updates would align Sandoz mission vision core values with investor ESG criteria and accelerating AI-driven pharmaceutical trends.

Embed Digital Transformation into the Mission

Explicitly reference AI-enabled drug development and end-to-end digital supply chains to make Sandoz Group purpose measurable and future-ready, supporting faster generics approvals and reduced time-to-market.

Make Environmental Stewardship a Core Value

Adopt targets such as net-zero by 2040 for operations and a 30% reduction in Scope 1–3 emissions by 2030 to meet ESG investor expectations and lower regulatory risk in API manufacturing.

Position Sustainability in the Vision Statement

Refine the Sandoz company values to state a vision like 'the world’s most sustainable and valued generics company,' tying brand purpose to measurable sustainability KPIs and consumer trust metrics.

Link Strategic Goals to Corporate Identity Metrics

Define Sandoz strategic goals with clear KPIs—market share growth in emerging markets, 10–15% CAGR in digital-health-enabled product lines by 2028, and quarterly ESG score improvements to track Sandoz corporate identity progress.

Improvements: While robust, the Sandoz mission and vision could be strengthened by explicitly incorporating the role of digital transformation and environmental sustainability; compared to competitors like Teva or Viatris, who emphasize green pharmacy and digital health, Sandoz Group mission vision core values remain more traditional. Pioneering 'sustainable access through digital innovation and high-quality medicine' would align Sandoz Group purpose with the 2025 trend of AI in drug development and supply chain management, and embedding environmental stewardship into the vision—positioning itself as the world’s most sustainable generics company—would meet rising ESG investment criteria and regulatory focus on chemical and API carbon footprints; see related analysis at Target Market of Sandoz Group